The Development Center with its state-of-the art laboratories and flexible pilot capacities is set to become Siegfried's global research and development hub for its Drug Products sites, strengthening the global network
The audit was commenced for newly renovated manufacturing Block 1, Block 2, and Block 3
The marketing authorisations for three generic drugs signifying advances in cancer treatment will considerably benefit thousands of patients by improving access, ensuring affordability
Standalone Q3 FY23 revenue stood at Rs. 626.5 crore as against Rs. 594.8 crore, a growth of 5% YoY
Krishna Institute of Medical Sciences to consider raising Rs. 300 crores
A committee of two Joint Drugs Controllers has been constituted at CDSCO to monitor the process of inspection, reporting, and subsequent action to ensure compliance to the Drugs & Cosmetics Act, 1940
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
The company has received payment towards completion of sale of the first tranche from Sekhmet Pharmaventures Private Limited.
India exported Bulk Drugs/Drug Intermediates worth Rs. 33,320 crore in financial year 2021-22.
Subscribe To Our Newsletter & Stay Updated
